Screener
Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Other Nonoperating Income Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| (Loss) income from operations | (2,240)) | 302) |
| Other (loss) income, net: | ||
| Interest income | 941 | 1,797 |
| Other expense, net | (488)) | (301)) |
| Change in fair value of warrant liability | 212 | 2,467 |
| (Loss) Income before income taxes | (1,575)) | 4,265) |
| Benefit (provision) for income taxes | (662) | (1,563)) |
| Net (loss) income | (2,237)) | 2,702) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — other nonoperating income expense of -$391K in Q2 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense increased by 22.9% year-over-year, from -$507K to -$391K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense has grown at a 18.2% compound annual growth rate (CAGR), from -$1.25M to -$1.74M.
- What does gyre pharmaceuticals — other nonoperating income expense mean?
- This includes income or expenses that fall outside the scope of the segment's primary business operations, such as foreign exchange fluctuations or miscellaneous financial items. It is used to identify peripheral financial impacts that do not reflect the core performance of the pharmaceutical business.
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude